As the evidence shows high expression of GLP-1-R with low Gleason grade, there is potential for using GLP-1-RA as an adjunct treatment to prevent disease progression, subsequently decreasing the dropout from AS and delaying the need for definitive PCa treatment. This evidence concerns the gene GLP1R and posterior cortical atrophy.